Flagship strategy with a 34-year track record

The strategy is a replica of ICG’s European Corporate but targets smaller mid-market transactions

The strategy is focused on creating and building life science companies addressing commercially attractive markets in diseases of high unmet medical needs

Secondary strategy focusing on LP-led transactions

The focus of US Mid-Market is on delivering performance through differentiated sourcing, tailored capital solutions, operational intensity, and execution of buy-and-build strategies.

ICG’s Special Opportunities platform is a credit-led strategy that aims to achieve equity-like returns by taking advantage of market dislocations in the European mid-market

ICGSE is one of the largest investors globally that is focused exclusively on GP-led transactions

Invests in a diversified portfolio of senior secured loans to established companies

Focuses on investing in primarily sponsor-backed North American middle-market companies

Focuses on European senior direct lending